Advertisement

The Role of Vaccines in Cancer Prevention

  • Samir N. Khleif
  • Helen Frederickson
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 106)

Abstract

From 1796, when Edward Jenner infected a young boy with cowpox in hopes of preventing smallpox, to the present day, vaccinations have changed the incidence of many diseases worldwide. The history of immunology actually predates Jenner to ancient China, India and Persia. The observation that recovery from a particular disease rendered people “immune” to a second episode of that same disease, led the Chinese to try to prevent smallpox by exposing uninfected people to pustule samples obtained from smallpox lesions. Jenner then improved the safety of vaccination by using a different, but similar, virus to vaccinate a young boy with cowpox rather than exposing him to the authentic smallpox virus. His observations that milkmaids who had developed cowpox lesions did not develop smallpox led Jenner to “vaccinate” twenty-three other people with cowpox and publish his findings in 1801 (1). This initial experiment serves as an important foundation of modern day immunology, and served to popularize the term “vaccine”, which is derived from the Latin word “vacca”, which means cow. Years later, Louis Pasteur, who had advanced the germ theory of infection, was able to prove that a disease could be prevented by exposure to “weakened” germs, which only caused harmless infections. His theories supported his development of the rabies vaccine.

Keywords

Cervical Cancer Major Histocompatibility Complex Major Histocompatibility Complex Class Cervical Intraepithelial Neoplasia Cancer Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Jenner E. The Origin of the Vaccine Inoculation. London: Shury, D.N., 1801.Google Scholar
  2. 2.
    Demiroglu H. Is prevention of cancer possible with tumor-specific vaccines? Med Hypotheses 1997; 49:281–4.PubMedGoogle Scholar
  3. 3.
    Goodwin PJ. Economic factors in cancer palliation--methodologic considerations. Cancer Treat Rev 1993; 19:59–65.PubMedGoogle Scholar
  4. 4.
    Rubens RD. Cost effectiveness in the treatment of advanced solid tumours. Eur J Cancer 1993; 4:604–5.Google Scholar
  5. 5.
    Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome [In Process Citation]. Semin Cell Dev Biol 2000; 11:141–8.PubMedGoogle Scholar
  6. 6.
    Rock KL, Rothstein L, Benacerraf B. Analysis of the association of peptides of optimal length to class I molecules on the surface of cells. Proc Natl Acad Sci, USA 1992; 89:8918–22.PubMedGoogle Scholar
  7. 7.
    Brodsky FM, Lem L, Bresnahan PA. Antigen processing and presentation [see comments]. Tissue Antigens 1996; 47:464–71.PubMedGoogle Scholar
  8. 8.
    Lurquin C, Van PA, et a. Structure of the gene of tum-transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 1989; 58:293303.PubMedGoogle Scholar
  9. 9.
    De Plaen E, Lurquin C, Van PA, et a. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of turn-antigen P9I A and identification of the tum-mutation. Proc Natl Acad Sci, USA 1988; 85:2274–8.PubMedGoogle Scholar
  10. 10.
    Davis MM, Chien Y. Topology and affinity of T-cell receptor mediated recognition of peptide-MHC complexes. Curr Opin Immunol 1993; 5:45–9.PubMedGoogle Scholar
  11. 11.
    Robinson MA, Kindt TJ. Major histo-compatibility complex antigens and genes. In: Paul WE, ed. Fundamental Immunology. New York: Raven Press, 1989:489.Google Scholar
  12. 12.
    Solheim JC. Class I MHC molecules: assembly and antigen presentation. Immunol Rev 1999; 172:11–9.PubMedGoogle Scholar
  13. 13.
    Hanau D, Saudrais C, Haegel-Kronenberger H, Bohbot A, De La Salle H, Salamero J. Fate of MHC class II molecules in human dendritic cells. Eur J Dermatol 1999; 9:7–12.PubMedGoogle Scholar
  14. 14.
    Batalia MA, Collins EJ. Peptide binding by class I and class II MHC molecules. Biopolymers 1997; 43:281–302.PubMedGoogle Scholar
  15. 15.
    Corradin G, Demotz S. Peptide-MHC complexes assembled following multiple pathways: an opportunity for the design of vaccines and therapeutic molecules. Hum Immunol 1997; 54:137–47.PubMedGoogle Scholar
  16. 16.
    Wubbolts R, Neef]es J. Intracellular transport and peptide loading of MHC class II molecules: regulation by chaperones and motors. Immunol Rev 1999; 172:189–208.PubMedGoogle Scholar
  17. 17.
    Pareja E, Tobes R, Martin J, Nieto A. The tetramer model: a new view of class II MHC molecules in antigenic presentation to T cells. Tissue Antigens 1997; 50:421–8.PubMedGoogle Scholar
  18. 18.
    Uenishi T, Hirohashi K, Tanaka H, Ikebe T, Kinoshita H. Spontaneous regression of a large hepatocellular carcinoma with portal vein tumor thrombi: report of a case. Surg Today 2000; 30:82–5.PubMedGoogle Scholar
  19. 19.
    Hachiya T, Koizumi T, Hayasaka M, et al. Spontaneous regression of primary mediastinal germ cell tumor. Jpn J Clin Oncol 1998; 28:281–3.PubMedGoogle Scholar
  20. 20.
    Markowska J, Markowska A. [Spontaneous tumor regression]. Ginekol Pol 1998; 69:39–44.PubMedGoogle Scholar
  21. 21.
    Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transpl 2000; 6:253–62.PubMedGoogle Scholar
  22. 22.
    Penn I. Overview of the problem of cancer in organ transplant recipients. Ann Transplant 1997; 2:5–6.PubMedGoogle Scholar
  23. 23.
    Konety BR, Tewari A, Howard RJ, et al. Prostate cancer in the post-transplant population. Urologic Society for Transplantation and Vascular Surgery. Urology 1998; 52:428–32.Google Scholar
  24. 24.
    Flattery MP. Incidence and treatment of cancer in transplant recipients. J Transpl Coord 1998; 8:105–10; quiz 111–2.PubMedGoogle Scholar
  25. 25.
    Sheil AG. Cancer in immune-suppressed organ transplant recipients: aetiology and evolution. Transplant Proc 1998; 30:2055–7.PubMedGoogle Scholar
  26. 26.
    Royal RE, Steinberg SM, Krouse RS, et al. Correlates of Response to IL-2 Therapy in Patients Treated for Metastatic Renal Cancer and Melanoma. Cancer J Sci Am 1996; 2:91.PubMedGoogle Scholar
  27. 27.
    Bourantas KL, Hatzimichael EC, Makis AC, et al. Prolonged interferon-alpha-2b treatment of hairy cell leukemia patients [letter]. Eur J Haematol 2000; 64:350–1.PubMedGoogle Scholar
  28. 28.
    Parkinson DR, Sznol M. High dose interleukin-2 in the therapy of metastatic renal cell carcinoma. Semon Oncol 1995; 22:61–66.Google Scholar
  29. 29.
    Stadler WM, Vogelzang NJ. Low dose interleukin-2 in the treatment of metaststic renal call carcinoma. Semin Oncol 1995; 22:67–73.PubMedGoogle Scholar
  30. 30.
    Landsteiner K, Chase MW. Experiments on transfer of cutaneous sensitivity to simple compounds. Proc Soc Exp Biol Med 1942; 49:688.Google Scholar
  31. 31.
    Tsomides TJ, Eisen HN. T-cell antigens in cancer. Proc Natl Acad Sci U S A 1994; 91:3487–9.PubMedGoogle Scholar
  32. 32.
    Pardoll DM. Tumour antigens. A new look for the 1990s [news; comment]. Nature 1994; 369:357.PubMedGoogle Scholar
  33. 33.
    Rapp F, Cory JM. Viral oncogenesis and the immune system. Cancer Detect Prey 1990; 14:437–44.Google Scholar
  34. 34.
    Nevins JR. Cell cycle targets of the DNA tumor viruses. Curr Opin Genet Dev 1994; 4.130–4.PubMedGoogle Scholar
  35. 35.
    Levine AJ. The origins of the small DNA tumor viruses. Adv Cancer Res 1994; 65:141–68.PubMedGoogle Scholar
  36. 36.
    van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643–7.PubMedGoogle Scholar
  37. 37.
    Bei R, Kantor J, Kashmiri SV, Abrams S, Schlom J. Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. J Immunother Emphasis Tumor Immunol 1994; 16:275–82.PubMedGoogle Scholar
  38. 38.
    Kawakami Y, Nishimura MI, Restifo NP, et al. T-cell recognition of human melanoma antigens. J Immunother 1993; 14:88–93.Google Scholar
  39. 39.
    Peace DJ, Chen W, Nelson H, Cheever MA. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol 1991; 146:2059–2065.PubMedGoogle Scholar
  40. 40.
    Yanuck M, Carbone DP, Pendleton DC, al. e. A mutant p53 or ras tumor suppressor protein is a target for peptide-induced CD8_ cytotoxic T cells. Cancer Res. 1993; 53:3257–3261.PubMedGoogle Scholar
  41. 41.
    Khleif SN, Abrams SI, Hamilton JM, et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 1999; 22:155–65.PubMedGoogle Scholar
  42. 42.
    Chapman PB, Morrissey DM, Panageas KS, et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res 2000; 6:874–9.PubMedGoogle Scholar
  43. 43.
    Sabbatini PJ, Kudryashov V, Ragupathi G, et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)- protein conjugate vaccine: a phase 1 trial. Int J Cancer 2000; 87:79–85.PubMedGoogle Scholar
  44. 44.
    Couch RB. Advances in influenza virus vaccine research. Ann N Y Acad Sci 1993; 685:803–12.PubMedGoogle Scholar
  45. 45.
    Brochier B, Kieny MP, Costy F, et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine [see comments]. Nature 1991; 354:520–2.PubMedGoogle Scholar
  46. 46.
    Parkin NT, Chiu P, Coelingh K. Genetically engineered live attenuated influenza A virus vaccine candidates. J Virol 1997; 71:2772–8.PubMedGoogle Scholar
  47. 47.
    Hassan JO, Curtiss R, 3rd. Effect of vaccination of hens with an avirulent strain of Salmonella typhimurium on immunity of progeny challenged with wild-Type Salmonella strains. Infect Immun 1996; 64:938–44.PubMedGoogle Scholar
  48. 48.
    Guleria I, Teitelbaum R, McAdam RA, Kalpana G, Jacobs WR, Jr., Bloom BR. Auxotrophic vaccines for tuberculosis. Nat Med 1996; 2:334–7.PubMedGoogle Scholar
  49. 49.
    Ellis RW. The new generation of recombinant viral subunit vaccines. Curr Opin Biotechnol 1996; 7:646–52.PubMedGoogle Scholar
  50. 50.
    Mitchell MS, Hare! W, Kempf RA, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990; 8:856–69.PubMedGoogle Scholar
  51. 51.
    McCune CS, Schapira DV, Henshaw EC. Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 1981; 47:1984–7.PubMedGoogle Scholar
  52. 52.
    Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial [see comments]. Lancet 1999; 353:345–50.PubMedGoogle Scholar
  53. 53.
    Chang EY, Chen CH, Ji H, et al. Antigen-specific cancer immunotherapy using a GM- CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000; 86:725–30.PubMedGoogle Scholar
  54. 54.
    Arvin AM, Mallory S, Moffat JF. Development of recombinant varicella-zoster virus vaccines. Contrib Microbiol 1999; 3:193–200.PubMedGoogle Scholar
  55. 55.
    Liljeqvist S, Stahl S. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J Biotechnol 1999; 73:1–33.PubMedGoogle Scholar
  56. 56.
    Restifo NP, Rosenberg SA. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol 1999; 11:50–7.PubMedGoogle Scholar
  57. 57.
    Rolph MS, Ramshaw IA. Recombinant viruses as vaccines and immunological tools [see comments]. Curr Opin Immunol 1997; 9:517–24.PubMedGoogle Scholar
  58. 58.
    Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271–96.PubMedGoogle Scholar
  59. 59.
    Takahashi H, Nakagawa Y, Yokomuro K, al. e. Induction of CD8+ CTL by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. International Immunology 1993; 5 (8):849–57.PubMedGoogle Scholar
  60. 60.
    Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD, Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity [see comments]. J Exp Med 1996; 183:283–7.PubMedGoogle Scholar
  61. 61.
    Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183:1357–65.PubMedGoogle Scholar
  62. 62.
    Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52–8.PubMedGoogle Scholar
  63. 63.
    Munoz N, Bosch FX. The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. Bull Pan Am Health Organ 1996; 30:362–77.PubMedGoogle Scholar
  64. 64.
    Dillner J, Knekt P, Schiller JT, Hakulinen T. Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. Bmj 1995; 311:1346.PubMedGoogle Scholar
  65. 65.
    Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer [see comments]. N Engl J Med 1997;337:1350–8.PubMedGoogle Scholar
  66. 66.
    Shingleton HM. Surgical treatment of cancer of the cervix. Eur J Gynaecol Oncol 1992; 13:45–52.PubMedGoogle Scholar
  67. 67.
    DeVilliers EM. Heterogeneity of the papilloma virus group. J Virol 1989; 63(11):4898–4903.Google Scholar
  68. 68.
    Mainman M. Cervical Neoplsia in Women With HIV Infection. Oncology 1994; 8:8394.Google Scholar
  69. 69.
    Kadish AS, Ho GY, Burk RD, et al. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 1997; 89:1285–93.PubMedGoogle Scholar
  70. 70.
    Schiffman MH, Bauer HM, Hoover RN, al. e. Epidemiologic evidence showing that human papilloma virus infection causes most cervical intraepitherlial neoplasia. JNCI 1993; 85(12):958–964.PubMedGoogle Scholar
  71. 71.
    Arends MJ, Donaldson YK, Duvall E, Wyllie AH, Bird CC. HPV in full thickness cervical biopsies: high prevalence in CIN 2 and CIN 3 detected by a sensitive PCR method. J Pathol 1991; 165:301–9.PubMedGoogle Scholar
  72. 72.
    Zur Hausen H, Scneider A. The role of papilloma-virus in human anogenetal cancer. In Salzman N., Howley PM (eds) The papoviredia, volt: Teh papilloma viruses. 1992:245–263.Google Scholar
  73. 73.
    McBride A, Khleif S. Antiviral Strategies For the Treatment of Cervical cancer. International Antiviral News 2000; 8:4–8.Google Scholar
  74. 74.
    Taichman LB, LaPorta RF. The expression of papillomavireses in epithelial cells. In: Salzman NP, Howley PM, eds. The Papovaviredia. Vol. 2. New York, NY: Plenum Press, 1987:109–139.Google Scholar
  75. 75.
    Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus LI major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89:12180–4.PubMedGoogle Scholar
  76. 76.
    Dvoretzky I, Shober R, Chattopadhyay SK, Lowy DR. A quantitative in vitro focus assay for bovine papilloma virus. Virology 1980; 103:369–75.PubMedGoogle Scholar
  77. 77.
    Lowy DR, Schiller JT. Papillomaviruses: prophylactic vaccine prospects. Biochim Biophys Acta 1999; 1423:M1–8.PubMedGoogle Scholar
  78. 78.
    Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995; 171:1387–98.PubMedGoogle Scholar
  79. 79.
    Volpers C, Schirmacher P, Streeck RE, Sapp M. Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 1994; 200:504–12.PubMedGoogle Scholar
  80. 80.
    Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996; 70:3298–301.PubMedGoogle Scholar
  81. 81.
    Kimbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. J Virol 1993; 67:6929–36.Google Scholar
  82. 82.
    Roden RB, Greenstone HL, Kimbauer R, et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996; 70:5875–83.PubMedGoogle Scholar
  83. 83.
    Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995; 92:11553–7.PubMedGoogle Scholar
  84. 84.
    Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPVinduced papilloma formation. Vaccine 1995; 13:1509–14.PubMedGoogle Scholar
  85. 85.
    Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959–63.PubMedGoogle Scholar
  86. 86.
    Nardelli-Haefliger D, Roden R, Balmelli C, Potts A, Schiller J, De Grandi P. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol 1999; 73:9609–13.PubMedGoogle Scholar
  87. 87.
    Dupuy C, Buzoni-Gatel D, Touze A, Bout D, Coursaget P. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 LI gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999; 73:9063–71.PubMedGoogle Scholar
  88. 88.
    Schreckenbergerab C, Sethupathia P, Kanjanahaluethaia A, et al. Induction of an HPV 6bLI-specific mucosal IgA response by DNA immunization. Vaccine 2000; 19:227–233.Google Scholar
  89. 89.
    Nindl I, Rindfleisch K, Lotz B, Schneider A, Durst M. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int J Cancer 1999; 82:203–7.PubMedGoogle Scholar
  90. 90.
    Chen L, Thomas EK, Hu SL, al. e. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991; 88:110–114.PubMedGoogle Scholar
  91. 91.
    Feltkamp MG, Smits HL, Vierboom MP, al. e. Vaccination with cytotoxic T lymphocyte epitope containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23:2242–2249.PubMedGoogle Scholar
  92. 92.
    Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997; 57:2943–50.PubMedGoogle Scholar
  93. 93.
    Alexander M, Salgaller ML, Celis E, et al. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 1996; 175:1586–93.PubMedGoogle Scholar
  94. 94.
    Kast WM, Brant RM, Drijfhout JW, al. e. Human Leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomaviris the 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. Immunotherapy 1993; 14:115–120.Google Scholar
  95. 95.
    Kast WM, Brandt RM, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994; 152:3904–12.PubMedGoogle Scholar
  96. 96.
    Ressing ME, Sette A, Brandt RM, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA- A*020I-binding peptides. J Immunol 1995; 154:5934–43.PubMedGoogle Scholar
  97. 97.
    Chen L, Mizuno MT, Singhal MC, al. e. Induction of cytotoxic T lymphocytes specific for syngeneic tumor expressing the E6 protein of human papillomavirus type 16. J Immunol 1992; 148(8):2617–2621.PubMedGoogle Scholar
  98. 98.
    Nindl I, Gissmann L, Fisher SG, Bribiesca LB, Berumen J, Muller M. The E7 protein of human papillomavirus (HPV) type 16 expressed by recombinant vaccinia virus can be used for detection of antibodies in sera from cervical cancer patients. J Virol Methods 1996; 62:81–5.PubMedGoogle Scholar
  99. 99.
    He Z, Wlazlo AP, Kowalczyk DW, et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000; 270:146–61.PubMedGoogle Scholar
  100. 100.
    Liu DW, Tsao YP, Kung JT, et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000; 74:2888–94.PubMedGoogle Scholar
  101. 101.
    Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999; 6:1972–81.PubMedGoogle Scholar
  102. 102.
    Murakami M, Gurski KJ, Marincola FM, Ackland J, Steller MA. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res 1999; 59:1184–7.PubMedGoogle Scholar
  103. 103.
    Hariharan K, Braslawsky G, Barnett RS, et al. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int J Oncol 1998; 12:1229–35.PubMedGoogle Scholar
  104. 104.
    Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343:481–92.PubMedGoogle Scholar
  105. 105.
    Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int.1 Cancer 1985; 35:35–42.Google Scholar
  106. 106.
    Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol 1997; 182:151–9PubMedGoogle Scholar
  107. 107.
    Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 1995; 85:744–50.PubMedGoogle Scholar
  108. 108.
    Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984; 310:1225–30.PubMedGoogle Scholar
  109. 109.
    Straus SE, Cohen JI, Tosato G, Meier J. NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993; 118:45–58.PubMedGoogle Scholar
  110. 110.
    Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma [see comments]. N Engl J Med 1995; 333:693–8.PubMedGoogle Scholar
  111. 111.
    de-The G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt’s lymphoma from Ugandan prospective study. Nature 1978; 274:756–61.PubMedGoogle Scholar
  112. 112.
    Hochberg FH, Miller G, Schooley RT, Hirsch MS, Feorino P, Henle W. Centralnervous-system lymphoma related to Epstein-Barr virus. N Engl J Med 1983; 309:745–8.PubMedGoogle Scholar
  113. 113.
    Imai S, Koizumi S, Sugiura M, et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A 1994; 91:9131–5.PubMedGoogle Scholar
  114. 114.
    Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation [see comments]. N Engl J Med 1995; 332:19–25.PubMedGoogle Scholar
  115. 115.
    Pallesen G, Hamilton-Dutoit SJ, Zhou X. The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin’s disease: two new developments in the EBV field. Adv Cancer Res 1993; 62:179–239.PubMedGoogle Scholar
  116. 116.
    Yao QY, Ogan P, Rowe M, Wood M, Rickinson AB. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 1989; 43:67–71.PubMedGoogle Scholar
  117. 117.
    Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 1998; 9:395–404.PubMedGoogle Scholar
  118. 118.
    Tanner J, Weis J, Fearon D, Whang Y, Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 1987; 50:203–13.PubMedGoogle Scholar
  119. 119.
    Thorley-Lawson DA, Poodry CA. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol 1982; 43:730–6.PubMedGoogle Scholar
  120. 120.
    Epstein MA, Morgan AJ, Finerty S, Randle BJ, Kirkwood JK. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 1985; 318:287–9.PubMedGoogle Scholar
  121. 121.
    Morgan AJ, Allison AC, Finerty S, Scullion FT, Byars NE, Epstein MA. Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use. J Med Virol 1989; 29:74–8.PubMedGoogle Scholar
  122. 122.
    Jackman WT, Mann KA, Hoffmann HJ, Spaete RR. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 1999; 17:660–8.PubMedGoogle Scholar
  123. 123.
    Gu SY, Huang TM, Ruan L, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995; 84:171–7.PubMedGoogle Scholar
  124. 124.
    Moss DJ, Suhrbier A, Elliott SL. Candidate vaccines for Epstein-Barr virus [editorial]. Bmj 1998; 317:423–4.PubMedGoogle Scholar
  125. 125.
    Chang MH, Chen CS, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group [see comments]. N Engl J Med 1997; 336:1855–9.PubMedGoogle Scholar
  126. 126.
    Popper H, Roth L, Purcell RH, Tennant BC, Gerin JL. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci U S A 1987; 84:866–70.PubMedGoogle Scholar
  127. 127.
    Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2:1129–33.PubMedGoogle Scholar
  128. 128.
    Prevention of Liver cancer. World Health Organization Technical Report. Vol. 691, 1983:1–30.Google Scholar
  129. 129.
    Zuckerman AJ. Prevention of primary liver cancer by immunization [editorial; comment]. N Engl J Med 1997; 336:1906–7.PubMedGoogle Scholar
  130. 130.
    Oda T. Viral hepatitis and hepatocellular carcinoma prevention strategy in Japan. Jpn J Cancer Res 1999; 90:1051–60.PubMedGoogle Scholar
  131. 131.
    The Jordan Report: Accelerated development of vaccines: NIAID/NIH, 2000:18–23.Google Scholar
  132. 132.
    Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 2000; 18:1436–47.PubMedGoogle Scholar
  133. 133.
    Hilleman MR. Recombinant vector vaccines in vaccinology. Dev Biol Stand 1994; 82:3–20.PubMedGoogle Scholar
  134. 134.
    Hilleman MR. Present status of recombinant hepatitis B vaccine. Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1988; 29 Suppl B:8B–15B.PubMedGoogle Scholar
  135. 135.
    Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan [see comments]. Jama 1996; 276:906–8.PubMedGoogle Scholar
  136. 136.
    Hsu HM, Chen DS, Chuang CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. Jama 1988; 260:2231–5.PubMedGoogle Scholar
  137. 137.
    Chen DS, Hsu NH, Sung JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. Jama 1987; 257:2597–603.PubMedGoogle Scholar
  138. 138.
    Mathei C, Van Damme P, Meheus A. Hepatitis B vaccine administration: comparison between jet-gun and syringe and needle. Vaccine 1997; 15:402–4.PubMedGoogle Scholar
  139. 139.
    Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996; 31:552–8.PubMedGoogle Scholar
  140. 140.
    Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team [see comments]. N Engl J Med 1992; 327:1899–905.PubMedGoogle Scholar
  141. 141.
    Simmonds P, McOmish F, Yap PL, et al. Sequence variability in the 5’ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 1993; 74:661–8.PubMedGoogle Scholar
  142. 142.
    Tokushige K, Wakita T, Pachuk C, et al. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology 1996; 24:14–20.PubMedGoogle Scholar
  143. 143.
    Arichi T, Saito T, Major ME, et al. Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV- specific cytotoxic T lymphocyte induction and protection from HCVrecombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. Proc Natl Acad Sci U S A 2000; 97:297–302.PubMedGoogle Scholar
  144. 144.
    Rowland M, Drumm B. Clinical significance of Helicobacter infection in children. Br Med Bull 1998; 54:95–103.PubMedGoogle Scholar
  145. 145.
    Feldman RA, Eccersley Al, Hardie JM. Epidemiology of Helicobacter pylori: acquisition, transmission, population prevalence and disease-to-infection ratio. Br Med Bull 1998; 54:39–53.PubMedGoogle Scholar
  146. 146.
    Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma [see comments]. Lancet 1991; 338:1175–6.PubMedGoogle Scholar
  147. 147.
    Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation [see comments]. Bmj 1991; 302:1302–5.PubMedGoogle Scholar
  148. 148.
    Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1:1311–5.PubMedGoogle Scholar
  149. 149.
    Vaira D, Holton J, Menegatti M, et al. New immunological assays for the diagnosis of Helicobacter pylori infection. Gut 1999; 45 Suppl 1:123–7.Google Scholar
  150. 150.
    Lee A, Chen M. Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun 1994; 62:3594–7.PubMedGoogle Scholar
  151. 151.
    Chen M, Lee A, Hazel! S. Immunisation against gastric helicobacter infection in a mouse/Helicobacter felis model [letter]. Lancet 1992; 339:1120–1.PubMedGoogle Scholar
  152. 152.
    Marchetti M, Arico B, Burroni D, Figura N, Rappuoli R, Ghiara P. Development of a mouse model of Helicobacter pylori infection that mimics human disease [see comments]. Science 1995; 267:1655–8.PubMedGoogle Scholar
  153. 153.
    Blanchard TG, Czinn SJ, Maurer R, Thomas WD, Soman G, Nedrud JG. Ureasespecific monoclonal antibodies prevent Helicobacter felis infection in mice. Infect Immun 1995; 63:1394–9.PubMedGoogle Scholar
  154. 154.
    Ghiara P, Rossi M, Marchetti M, et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun 1997; 65:4996–5002.PubMedGoogle Scholar
  155. 155.
    Tomb JF, White 0, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori [see comments] [published erratum appears in Nature 1997 Sep 25;389(6649):412]. Nature 1997; 388:539–47.PubMedGoogle Scholar
  156. 156.
    Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci U S A 1995; 92:6499–503.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Samir N. Khleif
  • Helen Frederickson

There are no affiliations available

Personalised recommendations